Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026
On March 10, 2026 Cantor Fitzgerald kept NBIX at Overweight and raised its price target to $195. The NBIX analyst rating update signals continued confidence in Ingrezza revenue prospects. We focus on the rating, the new $195 target, and what this means for investors and trading risk.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
